-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

Benzinga·08/12/2026 10:05:35
Listen to the news
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.